Eris Lifesciences announces Joint Venture with MJ Biopharm to offer insulin in India
The 70:30 Joint Venture will primarily engage in marketing and distribution of human and analogue insulin including Aspart, Glargine and Lispro and GLP-1 agonists and potentially other biopharma products in India
